{"id":46666,"date":"2022-07-28T07:01:43","date_gmt":"2022-07-28T05:01:43","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/genentech-to-present-scientific-progress-across-alzheimers-disease-pharmaceutical-and-diagnostic-portfolio-at-2022-aaic-annual-meeting\/"},"modified":"2022-07-28T07:01:43","modified_gmt":"2022-07-28T05:01:43","slug":"genentech-to-present-scientific-progress-across-alzheimers-disease-pharmaceutical-and-diagnostic-portfolio-at-2022-aaic-annual-meeting","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/genentech-to-present-scientific-progress-across-alzheimers-disease-pharmaceutical-and-diagnostic-portfolio-at-2022-aaic-annual-meeting\/","title":{"rendered":"Genentech to Present Scientific Progress Across Alzheimer\u2019s Disease Pharmaceutical and Diagnostic Portfolio at 2022 AAIC Annual Meeting"},"content":{"rendered":"<div>\n<p class=\"bwalignc\">\n<i>\u2013 Overview of two decades of research to be presented, including development of gantenerumab \u2013<\/i>\n<\/p>\n<p class=\"bwalignc\">\n<i>\u2013 Detailed results from Phase II study evaluating crenezumab in autosomal dominant Alzheimer&#8217;s disease \u2013<\/i>\n<\/p>\n<p class=\"bwalignc\">\n<i>\u2013 Data around biomarker selection for the Elecsys Amyloid Plasma Panel, a blood-based biomarker test to aid in the detection of people with amyloid pathology, recently granted FDA Breakthrough Device Designation \u2013<\/i>\n<\/p>\n<p>SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that data from 41 abstracts across its portfolio of Alzheimer\u2019s disease pharmaceuticals and diagnostics will be presented at the 2022 Alzheimer\u2019s Association International Conference (AAIC), which will be held in San Diego from July 31 &#8211; Aug. 4, 2022. Among the data are new presentations on Genentech\u2019s investigational subcutaneous anti-amyloid monoclonal antibody gantenerumab and the Elecsys<sup>\u00ae<\/sup> Amyloid Plasma Panel. Additionally, detailed results from the Alzheimer\u2019s Prevention Initiative Autosomal Dominant Alzheimer&#8217;s Disease (API ADAD) Trial evaluating the investigational monoclonal antibody crenezumab will be presented to inform future Alzheimer\u2019s prevention research.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220727005958\/en\/1138268\/5\/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220727005958\/en\/1138268\/21\/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg\"><\/a><\/p>\n<p>\n\u201cFollowing the science represents the foundation of our company. Our work in Alzheimer\u2019s over the past 20 years has helped transform disease understanding and ongoing approaches to clinical research,\u201d said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. \u201cWe are pleased to bring a strong scientific presence to this year\u2019s meeting, and we look forward to sharing our learnings in Alzheimer\u2019s biology, diagnosis and treatment with the broader community.\u201d\n<\/p>\n<p>\n<b>Gantenerumab Data Underscore Long-Term Commitment to Advancing Alzheimer\u2019s Therapeutic Research<\/b>\n<\/p>\n<p>\nThe history of the gantenerumab clinical development will be presented during an AAIC Scientific Session on Wednesday, Aug. 3 at 8:00 a.m. PT. This will include:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nHow the needs of people living with Alzheimer&#8217;s disease informed the design of current gantenerumab clinical studies and key learnings regarding treatment exposure, target population, enrichment strategies and ARIA management.\n<\/li>\n<li>\nFuture development plans, including opportunities to offer greater flexibility of treatment administration to meet the needs of people living with Alzheimer\u2019s.\n<\/li>\n<li>\nOpportunities to address barriers to inclusive research and equitable access.\n<\/li>\n<\/ul>\n<p>\nThe Phase III GRADUATE program in early Alzheimer\u2019s disease includes two global, double-blind, randomized, placebo-controlled clinical trials, GRADUATE I and II. Data will be available in Q4, 2022; topline results will be presented at the Clinical Trials on Alzheimer\u2019s Disease (CTAD) Conference on Wednesday, Nov. 30, 2022.\n<\/p>\n<p>\n<b>Crenezumab Data Advance Understanding of Prevention Efforts for Autosomal Dominant Alzheimer\u2019s<\/b>\n<\/p>\n<p>\nDetailed results from the Phase II Alzheimer\u2019s Prevention Initiative Autosomal Dominant Alzheimer&#8217;s Disease (API ADAD) Trial will be presented. The trial did not demonstrate a statistically significant clinical benefit in either of its co-primary endpoints, evaluating the ability of crenezumab to slow or prevent Alzheimer\u2019s disease in people with a specific genetic mutation after five to eight years of treatment compared with placebo. Data will be featured in the AAIC News Briefing on Tuesday, Aug. 2 at 7:00 a.m. PT followed by a Scientific Session at 8:00 a.m. PT. Researchers will discuss the trial\u2019s design, clinical outcomes, brain imaging and cerebrospinal fluid (CSF) biomarker findings.\n<\/p>\n<p>\n<b>Diagnostics Continues to Drive Innovation in Improving Timely Diagnosis of Alzheimer\u2019s<\/b>\n<\/p>\n<p>\nStudy results leading to the selection of blood-based biomarkers used in the Roche Diagnostics Elecsys Amyloid Plasma Panel, a test with the potential to aid in the detection of people with amyloid pathology, will be presented on Tuesday, Aug. 2. The Elecsys Amyloid Plasma Panel, which was recently granted FDA Breakthrough Device Designation, has the potential to better direct people towards a confirmatory Alzheimer\u2019s diagnosis, either with amyloid positron emission tomography (PET) or cerebrospinal fluid (CSF) testing, where appropriate.\n<\/p>\n<p>\n<b>Data Presentations Across Genentech\u2019s Alzheimer\u2019s Disease Portfolio<\/b>\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Investigational Medicine and\/or Diagnostics<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Abstract Title<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Presentation Number (type), Session Title<\/b>\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\n<b>Presentation Date + Time (PT)<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"11\">\n<p class=\"bwcellpmargin\">\nGantenerumab\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nOpen RoAD: Design and baseline characteristics of an open-label rollover study evaluating long-term safety and tolerability of subcutaneous gantenerumab in participants with early Alzheimer\u2019s disease\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nIn-Person Poster\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\nSunday, July 31\n<\/p>\n<p class=\"bwcellpmargin\">\n7:00 a.m. &#8211; 11:55 p.m.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nLinking amyloid to clinical outcome: A quantitative semi-mechanistic model based on the A\/T\/N biomarker framework to simulate the natural history of Alzheimer\u2019s disease and the effects of anti-amyloid treatment.\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nIn-Person Poster\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\nSunday, July 31\n<\/p>\n<p class=\"bwcellpmargin\">\n7:00 a.m. &#8211; 11:55 p.m.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nUsing an external control to contextualize efficacy data from patients with prodromal and mild Alzheimer\u2019s disease treated with gantenerumab in SCarlet RoAD and Marguerite RoAD open-label extension studies\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nHybrid Oral Session\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\nSunday, July 31\n<\/p>\n<p class=\"bwcellpmargin\">\n3:05 p.m. &#8211; 3:15 p.m.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nBaseline participant characteristics of GRADUATION: a study to evaluate once-weekly subcutaneous administration of gantenerumab\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nVirtual Only Poster\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\nSunday, July 31\n<\/p>\n<p class=\"bwcellpmargin\">\n7:00 a.m. &#8211; 11:55 p.m.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nMortality across the Alzheimer&#8217;s disease clinical stages: an analysis using the U.S. National Alzheimer\u2019s Coordinating Center Uniform Data Set\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nVirtual Only Poster\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\nSunday, July 31\n<\/p>\n<p class=\"bwcellpmargin\">\n7:00 a.m. &#8211; 11:55 p.m.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nAllowing \u201crescue therapy\u201d in preclinical Alzheimer\u2019s trials\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nIn-Person Poster\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\nTuesday, Aug. 2\n<\/p>\n<p class=\"bwcellpmargin\">\n12:00 a.m. &#8211; 11:59 p.m.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nThe clinical development history of gantenerumab\u201a a subcutaneous anti-A\u03b2 monoclonal antibody for early Alzheimer\u2019s disease: Building on lessons from the past and paving a path for the future\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nHybrid Focussed Topic Session\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\nWednesday, Aug. 3\n<\/p>\n<p class=\"bwcellpmargin\">\n8:00 a.m. &#8211; 8:45 a.m.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nGantenerumab treatment increases plasma beta-amyloid (1\u201342) and decreases plasma ptau\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nIn-Person Poster\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\nWednesday, Aug. 3\n<\/p>\n<p class=\"bwcellpmargin\">\n12:00 a.m. &#8211; 11:59 p.m.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nBlood-based biomarker pre-screening in the SKYLINE secondary prevention study with gantenerumab\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nIn-Person Poster\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\nWednesday, Aug. 3\n<\/p>\n<p class=\"bwcellpmargin\">\n12:00 a.m. &#8211; 11:59 p.m.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nDetermining the amyloid PET and CSF inclusion criteria for the SKYLINE secondary prevention study with gantenerumab\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nIn-Person Poster\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\nWednesday, Aug. 3\n<\/p>\n<p class=\"bwcellpmargin\">\n12:00 a.m. &#8211; 11:59 p.m.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nComparing ARIA-E severity scales and effects of treatment management thresholds\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nIn-Person Poster\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\nWednesday, Aug. 3\n<\/p>\n<p class=\"bwcellpmargin\">\n12:00 a.m. &#8211; 11:59 p.m.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"5\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\nCrenezumab\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nElectrocardiogram differences in cognitively unimpaired\n<\/p>\n<p class=\"bwcellpmargin\">\nPSEN1-E280A carriers\n<\/p>\n<p class=\"bwcellpmargin\">\nand non-carriers\n<\/p>\n<p class=\"bwcellpmargin\">\nfrom the Alzheimer\u2019s\n<\/p>\n<p class=\"bwcellpmargin\">\nPrevention Initiative\n<\/p>\n<p class=\"bwcellpmargin\">\nAutosomal-Dominant\n<\/p>\n<p class=\"bwcellpmargin\">\nAlzheimer\u2019s Disease\n<\/p>\n<p class=\"bwcellpmargin\">\nColombia trial\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nVirtual Only Poster\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\nSunday, July 31\n<\/p>\n<p class=\"bwcellpmargin\">\n7:00 a.m. &#8211; 11:55 p.m.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nLongitudinal lumbar puncture tolerability and adherence in the Alzheimer\u2019s Prevention Initiative Autosomal-Dominant Alzheimer\u2019s Disease Colombia Trial\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nVirtual Only Poster\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\nSunday, July 31\n<\/p>\n<p class=\"bwcellpmargin\">\n7:00 a.m. &#8211; 11:55 p.m.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nAge at menarche and relationship to baseline brain imaging and cognitive measurements related to PSEN1 E280A mutation from the API ADAD Trial\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPoster\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\nWednesday, Aug. 3\n<\/p>\n<p class=\"bwcellpmargin\">\n12:00 a.m. &#8211; 11:59 p.m.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nAPI ADAD Colombia Trial initial findings: a randomized, double-blind, placebo-controlled, parallel-group study in cognitively unimpaired PSEN1 E280A mutation carriers evaluating efficacy and safety of crenezumab\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nFeatured Topic Session\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\nTuesday, Aug. 2\n<\/p>\n<p class=\"bwcellpmargin\">\n8:00 a.m. &#8211; 8:45 a.m.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nClinical Profiles of Persons Who Progress to Cognitive Impairment in the Alzheimer\u2019s Prevention Initiative (API) ADAD Colombia Trial\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nIn-Person Poster\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\nSunday, July 31\n<\/p>\n<p class=\"bwcellpmargin\">\n9:00 a.m. &#8211; 4:15 p.m.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"5\">\n<p class=\"bwcellpmargin\">\nSemorinemab\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nIn vivo head-to-head comparison of [18f]GTP1 and [18f]PI2620 in Alzheimer\u2019s disease\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nIn-Person Poster\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\nSaturday, July 30\n<\/p>\n<p class=\"bwcellpmargin\">\n12:25 p.m. &#8211; 1:40 p.m.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPrognostic utility of baseline [18F]GTP1 tau PET signal for subsequent cognitive and functional decline in prodromal-to-mild Alzheimer\u2019s disease\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nIn-Person Poster\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\nSaturday, July 30\n<\/p>\n<p class=\"bwcellpmargin\">\n12:25 p.m. &#8211; 1:40 p.m.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nEvaluation of longitudinal [18F]GTP1 tau burden metrics in the Tauriel Phase II study\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nHybrid Oral Session\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\nSunday, July 31\n<\/p>\n<p class=\"bwcellpmargin\">\n11:35 a.m. &#8211; 11:45 a.m.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCharacterizing progressive speech changes in prodromal-to-mild Alzheimer\u2019s disease using natural language processing\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nIn-Person Poster\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\nSunday, July 31\n<\/p>\n<p class=\"bwcellpmargin\">\n12:00 a.m. &#8211; 11:59 p.m.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nSelecting appropriate meaningful change thresholds for trials of early (prodromal-to-mild) AD: A caregiver-rated, anchor-based analysis based on the Tauriel Study\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nVirtual Oral Session\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\nMonday, Aug. 1\n<\/p>\n<p class=\"bwcellpmargin\">\n12:05 p.m. &#8211; 12:15 p.m.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"19\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\nDiagnostics\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCurrent diagnostic pathways for Alzheimer&#8217;s Disease &#8211; a comparison of six countries\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nIn-Person Poster\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\nSunday, July 31\n<\/p>\n<p class=\"bwcellpmargin\">\n7:00 a.m. &#8211; 11:55 p.m.\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nImproving statistical modeling with a neuropathology-Based APOE Genetic Risk Score\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nVirtual Only Poster\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\nSunday, July 31\n<\/p>\n<p class=\"bwcellpmargin\">\n7:00 a.m. &#8211; 11:55 p.m.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCerebrospinal fluid soluble TREM2 is associated with accelerated AD-related longitudinal neurodegeneration in preclinical Alzheimer\u2019s disease\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nVirtual Only poster\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\nSunday, July 31\n<\/p>\n<p class=\"bwcellpmargin\">\n7:00 a.m. &#8211; 11:55 p.m.\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nBest combination of CSF biomarkers for predicting cognitive decline and clinical progression: A multi-cohort study\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nVirtual Oral Session\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\nSunday, July 31\n<\/p>\n<p class=\"bwcellpmargin\">\n9:15 a.m. \u2013 9:25 a.m.\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nSecond-generation fully automated Elecsys cerebrospinal fluid immunoassays demonstrate high precision, reproducibility, and sample stability suitable for clinical routine\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nIn-Person Poster\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\nMonday, Aug. 1\n<\/p>\n<p class=\"bwcellpmargin\">\n12:00 a.m. &#8211; 11:59 p.m.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nModifying effect of AD pathology in the association between CSF synaptic biomarkers and brain function and structure in preclinical Alzheimer\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nVirtual Lightning Presentation Round\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\nMonday, Aug. 1\n<\/p>\n<p class=\"bwcellpmargin\">\n8:00 a.m. &#8211; 8:04 a.m.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nAir pollution has a more deleterious effect on Alzheimer\u2019s disease biomarkers in genetic predisposition to larger hippocampal volumes\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nVirtual Oral Session\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\nMonday, Aug. 1\n<\/p>\n<p class=\"bwcellpmargin\">\n3:03 p.m. &#8211; 3:15 p.m.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nAssociations between semantic memory for proper names in story recall and CSF amyloid and tau in a cognitively unimpaired sample\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nIn-Person Poster\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\nMonday, Aug. 1\n<\/p>\n<p class=\"bwcellpmargin\">\n12:00 a.m. &#8211; 11:59 p.m.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nSex differences in CSF biomarkers profile of accelerated biological aging individuals at risk of AD\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nIn-Person Poster\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\nMonday, Aug. 1\n<\/p>\n<p class=\"bwcellpmargin\">\n12:00 a.m. &#8211; 11:59 p.m.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nImpact of CSF pTau\/A\u03b242 on brain structure and metabolism in middle-aged cognitively unimpaired individuals\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nIn-Person Poster\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\nTuesday, Aug. 2\n<\/p>\n<p class=\"bwcellpmargin\">\n12:00 a.m. &#8211; 11:59 p.m.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nClinical performance and robustness of blood-based biomarkers for early detection of amyloid pathology associated with Alzheimer\u2019s disease\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nIn-Person Poster\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\nTuesday, Aug. 2\n<\/p>\n<p class=\"bwcellpmargin\">\n12:00 a.m. &#8211; 11:59 p.m.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPredicting CSF neurogranin and neurofilament light chain protein levels with a neuropathology-based APOE genetic risk score\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nIn-Person Poster\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\nTuesday, Aug. 2\n<\/p>\n<p class=\"bwcellpmargin\">\n12:00 a.m. &#8211; 11:59 p.m.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nImpact of pre-analytical factors on blood-based biomarkers of Alzheimer\u2019s disease\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nIn-Person Poster\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\nTuesday, Aug. 2\n<\/p>\n<p class=\"bwcellpmargin\">\n12:00 a.m. &#8211; 11:59 p.m.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nThe effects of stressful life events on Alzheimer\u2019s disease biomarkers, neuroinflammation and brain integrity in later life: a life course perspective\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nHybrid Lightning Presentation Round\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\nWednesday, Aug. 3\n<\/p>\n<p class=\"bwcellpmargin\">\n8:08 a.m. &#8211; 8:12 a.m.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nGut microbe-modulated metabolites are longitudinally associated with higher neurodegeneration biomarkers in cerebrospinal fluid (CSF)\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nHybrid Oral Session\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\nWednesday, Aug. 3\n<\/p>\n<p class=\"bwcellpmargin\">\n2:45 p.m. &#8211; 2:55 p.m.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nStructural and metabolic brain correlates of excess A\u03b2 accumulation at the earliest AD continuum\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nIn-Person Poster\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\nWednesday, Aug. 3\n<\/p>\n<p class=\"bwcellpmargin\">\n12:00 a.m. &#8211; 11:59 p.m.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nBiological brain age prediction using machine learning on structural neuroimaging data: multi-cohort validation against biomarkers of Alzheimer\u2019s disease and neurodegeneration\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nIn-Person Poster\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\nWednesday, Aug. 3\n<\/p>\n<p class=\"bwcellpmargin\">\n12:00 a.m. &#8211; 11:59 p.m.\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nRoadmap to implementation of a fully automated blood-based biomarker test to facilitate diagnosis and treatment in early Alzheimer\u2019s disease\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nIn-Person Poster\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\nWednesday, Aug. 3\n<\/p>\n<p class=\"bwcellpmargin\">\n12:00 a.m. &#8211; 11:59 p.m.\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nBecoming physically active or maintaining activity during midlife is associated with biomarkers of amyloid-beta, microglia, and temporal lobe integrity\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nHybrid Oral Session\n<\/p>\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<p class=\"bwcellpmargin\">\nThursday, Aug. 4\n<\/p>\n<p class=\"bwcellpmargin\">\n10:05 a.m. &#8211; 10:15 a.m.\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n<b>About Genentech in Alzheimer\u2019s disease<\/b>\n<\/p>\n<p>\nWith more than two decades of scientific research in Alzheimer\u2019s, Genentech and Roche are working towards a day when we can detect the disease early and stop its progression to preserve what makes people who they are. Today, the companies\u2019 Alzheimer\u2019s portfolio spans investigational medicines for different targets, types and stages of the disease. It also includes diagnostic tools, including digital, blood-based and cerebrospinal fluid (CSF) tests, aiming to more effectively detect, diagnose, and monitor the disease. Yet the challenges of Alzheimer\u2019s go well beyond the capabilities of science, and making a meaningful impact requires collaboration both within the Alzheimer\u2019s community and outside of healthcare. Genentech and Roche will continue to work together with numerous partners with the hope of transforming millions of lives.\n<\/p>\n<p>\n<b>About Gantenerumab<\/b>\n<\/p>\n<p>\nGantenerumab is a fully-human monoclonal IgG1 antibody, an investigational medicine that is subcutaneously administered and designed to target and bind to aggregated forms of beta-amyloid and activate immune cells in the brain (microglia) to clear amyloid plaques and prevent further accumulation.\n<\/p>\n<p>\nGantenerumab is currently being investigated in eight clinical trials, including:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<b>GRADUATE I and II<\/b>, two Phase III studies investigating the efficacy and safety of gantenerumab compared with placebo in up to 1,000 participants per study who have early Alzheimer\u2019s over 27 months. Results are expected in Q4, 2022.\n<\/li>\n<li>\n<b>GRADUATION<\/b>, an open-label study to evaluate the pharmacodynamic effects of once weekly administration in participants with early Alzheimer\u2019s disease.\n<\/li>\n<li>\n<b>Post-GRADUATE<\/b>, a rollover open-label study for GRADUATE I and II to continue assessing the efficacy and safety of gantenerumab in participants with early Alzheimer\u2019s disease.\n<\/li>\n<li>\n<b>Open RoAD<\/b>, a rollover open-label study for the former SCarlet RoAD and Marguerite RoAD OLEs to continue to evaluate the safety and tolerability of long-term administration of gantenerumab in participants with Alzheimer\u2019s disease.\n<\/li>\n<li>\n<b>DIAN-TU-002 Primary Prevention<\/b>, an investigator-initiated study evaluating whether Alzheimer\u2019s can be prevented in people with a genetic predisposition to developing rare, early-onset forms of the disease called Autosomal Dominant AD (ADAD). Unlike most Alzheimer\u2019s disease prevention studies, it enrolls people up to 25 years before the disease has started in the brain.\n<\/li>\n<li>\n<b>DIAN-TU-001 OLE<\/b>, an exploratory extension study in people with ADAD who presented with or were close to the expected symptoms of Alzheimer\u2019s disease at baseline of the double-blind study, aiming to further investigate the relationship of biomarker changes with cognitive and clinical findings.\n<\/li>\n<li>\n<b>SKYLINE<\/b>, a Phase III secondary prevention trial to evaluate the efficacy and safety of gantenerumab in participants at risk for or at the earliest stages of Alzheimer&#8217;s disease.\n<\/li>\n<\/ul>\n<p>\n<b>About Crenezumab<\/b>\n<\/p>\n<p>\nCrenezumab is an investigational, monoclonal antibody designed to neutralize neurotoxic oligomers, a form of beta-amyloid. Crenezumab has an antibody backbone (IgG4) designed to minimize the inflammatory response in the brain, which may result in a lower risk of certain MRI (magnetic resonance imaging) abnormalities known as ARIA (Amyloid-Related Imaging Abnormalities). The investigational medicine is being developed by Genentech and is part of a collaboration with AC Immune SA.\n<\/p>\n<p>\n<b>About Semorinemab<\/b>\n<\/p>\n<p>\nSemorinemab is an investigational monoclonal anti-tau antibody that targets the N-terminal portion of the tau protein, and is designed to bind to tau and slow its spread between neurons. In tauopathies such as Alzheimer\u2019s disease, tau misfolds and forms tangles, which cause cell damage and ultimately neuronal death. It is hypothesized that abnormal tau protein then spreads between neurons, gradually involving more areas of the brain, and leading to clinical disease progression. Tau-targeting antibody therapies are designed to slow or stop this process of tau spread. The investigational medicine is being developed by Genentech and is part of a collaboration with AC Immune SA.\n<\/p>\n<p>\n<b>About the Roche Diagnostics Elecsys<sup>\u00ae<\/sup> Amyloid Plasma Panel<\/b>\n<\/p>\n<p>\nThe Elecsys Amyloid Plasma Panel measures phosphorylated Tau (pTau) 181 protein assay and apolipoprotein (APOE) E4 assay in human blood plasma. Elevations in pTau occur in early stages of Alzheimer\u2019s, while the presence of APOE E4 constitutes the most common genetic risk factor for Alzheimer\u2019s disease. The result is intended for consideration in conjunction with other clinical information to advise physicians on whether there is a need for further confirmatory testing for Alzheimer\u2019s disease with amyloid positron emission tomography (PET) or cerebrospinal fluid (CSF) testing. Patients testing negative with the Elecsys Amyloid Plasma Panel are unlikely to be amyloid positive and should be investigated for other causes of cognitive decline.\n<\/p>\n<p>\n<b>About Genentech in Neuroscience<\/b>\n<\/p>\n<p>\nNeuroscience is a major focus of research and development at Genentech and Roche. Our goal is to pursue groundbreaking science to develop new treatments that help improve the lives of people with chronic and potentially devastating diseases.\n<\/p>\n<p>\nGenentech and Roche are investigating more than a dozen medicines for neurological disorders, including multiple sclerosis, stroke, Alzheimer\u2019s disease, Parkinson\u2019s disease and autism spectrum disorder. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neuroscience today.\n<\/p>\n<p>\n<b>About Genentech<\/b>\n<\/p>\n<p>\nFounded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gene.com%2F&amp;esheet=52793769&amp;newsitemid=20220727005958&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.gene.com.&amp;index=1&amp;md5=26f9ead3fa1d1138877252c645e2d971\" rel=\"nofollow noopener\" shape=\"rect\">http:\/\/www.gene.com.<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nFor Questions: <a target=\"_blank\" href=\"&#x6d;&#x61;&#105;lt&#x6f;&#x3a;&#104;&#117;r&#x64;&#x6c;&#101;&#46;j&#x75;&#x73;&#x74;&#105;n&#64;&#x67;&#x65;&#110;&#101;&#46;&#x63;&#x6f;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#104;&#x75;r&#100;&#x6c;e&#46;&#x6a;u&#115;&#x74;i&#110;&#x40;g&#101;&#x6e;e&#46;&#x63;o&#109;<\/a>\n<\/p>\n<p>\nMedia Contact:<br \/>\n<br \/>Justin Hurdle (650) 467-6800\n<\/p>\n<p>\nAdvocacy Contact:<br \/>\n<br \/>Jen\u00e9e D. Williams (650) 303-2958\n<\/p>\n<p>\nInvestor Contacts:<br \/>\n<br \/>Loren Kalm (650) 225-3217<br \/>\n<br \/>Karl Mahler 011 41 61 687 8503\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u2013 Overview of two decades of research to be presented, including development of gantenerumab \u2013 \u2013 Detailed results from Phase II study evaluating crenezumab in autosomal dominant Alzheimer&#8217;s disease \u2013 \u2013 Data around biomarker selection for the Elecsys Amyloid Plasma Panel, a blood-based biomarker test to aid in the detection of people with amyloid pathology, &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/genentech-to-present-scientific-progress-across-alzheimers-disease-pharmaceutical-and-diagnostic-portfolio-at-2022-aaic-annual-meeting\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46666","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Genentech to Present Scientific Progress Across Alzheimer\u2019s Disease Pharmaceutical and Diagnostic Portfolio at 2022 AAIC Annual Meeting - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/genentech-to-present-scientific-progress-across-alzheimers-disease-pharmaceutical-and-diagnostic-portfolio-at-2022-aaic-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genentech to Present Scientific Progress Across Alzheimer\u2019s Disease Pharmaceutical and Diagnostic Portfolio at 2022 AAIC Annual Meeting - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"\u2013 Overview of two decades of research to be presented, including development of gantenerumab \u2013 \u2013 Detailed results from Phase II study evaluating crenezumab in autosomal dominant Alzheimer&#8217;s disease \u2013 \u2013 Data around biomarker selection for the Elecsys Amyloid Plasma Panel, a blood-based biomarker test to aid in the detection of people with amyloid pathology, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/genentech-to-present-scientific-progress-across-alzheimers-disease-pharmaceutical-and-diagnostic-portfolio-at-2022-aaic-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-28T05:01:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220727005958\/en\/1138268\/21\/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"13 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genentech-to-present-scientific-progress-across-alzheimers-disease-pharmaceutical-and-diagnostic-portfolio-at-2022-aaic-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genentech-to-present-scientific-progress-across-alzheimers-disease-pharmaceutical-and-diagnostic-portfolio-at-2022-aaic-annual-meeting\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Genentech to Present Scientific Progress Across Alzheimer\u2019s Disease Pharmaceutical and Diagnostic Portfolio at 2022 AAIC Annual Meeting\",\"datePublished\":\"2022-07-28T05:01:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genentech-to-present-scientific-progress-across-alzheimers-disease-pharmaceutical-and-diagnostic-portfolio-at-2022-aaic-annual-meeting\\\/\"},\"wordCount\":2639,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genentech-to-present-scientific-progress-across-alzheimers-disease-pharmaceutical-and-diagnostic-portfolio-at-2022-aaic-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220727005958\\\/en\\\/1138268\\\/21\\\/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genentech-to-present-scientific-progress-across-alzheimers-disease-pharmaceutical-and-diagnostic-portfolio-at-2022-aaic-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genentech-to-present-scientific-progress-across-alzheimers-disease-pharmaceutical-and-diagnostic-portfolio-at-2022-aaic-annual-meeting\\\/\",\"name\":\"Genentech to Present Scientific Progress Across Alzheimer\u2019s Disease Pharmaceutical and Diagnostic Portfolio at 2022 AAIC Annual Meeting - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genentech-to-present-scientific-progress-across-alzheimers-disease-pharmaceutical-and-diagnostic-portfolio-at-2022-aaic-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genentech-to-present-scientific-progress-across-alzheimers-disease-pharmaceutical-and-diagnostic-portfolio-at-2022-aaic-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220727005958\\\/en\\\/1138268\\\/21\\\/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg\",\"datePublished\":\"2022-07-28T05:01:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genentech-to-present-scientific-progress-across-alzheimers-disease-pharmaceutical-and-diagnostic-portfolio-at-2022-aaic-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genentech-to-present-scientific-progress-across-alzheimers-disease-pharmaceutical-and-diagnostic-portfolio-at-2022-aaic-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genentech-to-present-scientific-progress-across-alzheimers-disease-pharmaceutical-and-diagnostic-portfolio-at-2022-aaic-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220727005958\\\/en\\\/1138268\\\/21\\\/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220727005958\\\/en\\\/1138268\\\/21\\\/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genentech-to-present-scientific-progress-across-alzheimers-disease-pharmaceutical-and-diagnostic-portfolio-at-2022-aaic-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Genentech to Present Scientific Progress Across Alzheimer\u2019s Disease Pharmaceutical and Diagnostic Portfolio at 2022 AAIC Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Genentech to Present Scientific Progress Across Alzheimer\u2019s Disease Pharmaceutical and Diagnostic Portfolio at 2022 AAIC Annual Meeting - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/genentech-to-present-scientific-progress-across-alzheimers-disease-pharmaceutical-and-diagnostic-portfolio-at-2022-aaic-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Genentech to Present Scientific Progress Across Alzheimer\u2019s Disease Pharmaceutical and Diagnostic Portfolio at 2022 AAIC Annual Meeting - Pharma Trend","og_description":"\u2013 Overview of two decades of research to be presented, including development of gantenerumab \u2013 \u2013 Detailed results from Phase II study evaluating crenezumab in autosomal dominant Alzheimer&#8217;s disease \u2013 \u2013 Data around biomarker selection for the Elecsys Amyloid Plasma Panel, a blood-based biomarker test to aid in the detection of people with amyloid pathology, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/genentech-to-present-scientific-progress-across-alzheimers-disease-pharmaceutical-and-diagnostic-portfolio-at-2022-aaic-annual-meeting\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-28T05:01:43+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220727005958\/en\/1138268\/21\/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/genentech-to-present-scientific-progress-across-alzheimers-disease-pharmaceutical-and-diagnostic-portfolio-at-2022-aaic-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/genentech-to-present-scientific-progress-across-alzheimers-disease-pharmaceutical-and-diagnostic-portfolio-at-2022-aaic-annual-meeting\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Genentech to Present Scientific Progress Across Alzheimer\u2019s Disease Pharmaceutical and Diagnostic Portfolio at 2022 AAIC Annual Meeting","datePublished":"2022-07-28T05:01:43+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/genentech-to-present-scientific-progress-across-alzheimers-disease-pharmaceutical-and-diagnostic-portfolio-at-2022-aaic-annual-meeting\/"},"wordCount":2639,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/genentech-to-present-scientific-progress-across-alzheimers-disease-pharmaceutical-and-diagnostic-portfolio-at-2022-aaic-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220727005958\/en\/1138268\/21\/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/genentech-to-present-scientific-progress-across-alzheimers-disease-pharmaceutical-and-diagnostic-portfolio-at-2022-aaic-annual-meeting\/","url":"https:\/\/pharma-trend.com\/en\/genentech-to-present-scientific-progress-across-alzheimers-disease-pharmaceutical-and-diagnostic-portfolio-at-2022-aaic-annual-meeting\/","name":"Genentech to Present Scientific Progress Across Alzheimer\u2019s Disease Pharmaceutical and Diagnostic Portfolio at 2022 AAIC Annual Meeting - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/genentech-to-present-scientific-progress-across-alzheimers-disease-pharmaceutical-and-diagnostic-portfolio-at-2022-aaic-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/genentech-to-present-scientific-progress-across-alzheimers-disease-pharmaceutical-and-diagnostic-portfolio-at-2022-aaic-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220727005958\/en\/1138268\/21\/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg","datePublished":"2022-07-28T05:01:43+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/genentech-to-present-scientific-progress-across-alzheimers-disease-pharmaceutical-and-diagnostic-portfolio-at-2022-aaic-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/genentech-to-present-scientific-progress-across-alzheimers-disease-pharmaceutical-and-diagnostic-portfolio-at-2022-aaic-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/genentech-to-present-scientific-progress-across-alzheimers-disease-pharmaceutical-and-diagnostic-portfolio-at-2022-aaic-annual-meeting\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220727005958\/en\/1138268\/21\/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220727005958\/en\/1138268\/21\/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/genentech-to-present-scientific-progress-across-alzheimers-disease-pharmaceutical-and-diagnostic-portfolio-at-2022-aaic-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Genentech to Present Scientific Progress Across Alzheimer\u2019s Disease Pharmaceutical and Diagnostic Portfolio at 2022 AAIC Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46666","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46666"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46666\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46666"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46666"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46666"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}